ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 524

Plasma Concentrations of Antibodies to Porphyromonas Gingivalis Are Increased before Onset of Symptom of Rheumatoid Arthritis

Linda Johansson1, Natalia Sherina2, Nastya Kharlamova3, Barbro Larsson2, Lena Israelsson4, Solbritt Rantapaa-Dahlqvist5 and Karin Lundberg3, 11Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, 22Rheumatology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden, 3Rheumatology Unit, Department of Medicine, Solna, Karolinska Institute, Stockholm, Sweden, 4Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 5Department of Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: ACPA, P. Gingivalis, Periodontitis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Chronic periodontitis has been considered as an important determinant in both occurrence and severity of rheumatoid arthritis (RA). It has been hypothesized that citrullination by the periodontal pathogen Porphyromonas gingivalis may play an important role in the development of RA-specific autoimmunity, by breaking immune tolerance to citrullinated proteins and trigger the production of anti-citrullinated protein antibodies (ACPA). In support of this hypothesis, we have recently demonstrated elevated anti-P. gingivalis antibody levels in RA compared to controls, specifically in ACPA+ RA. The aim of the present study was to further investigate the role of P. gingivalis in RA aetiology, by analysing the anti-P. gingivalis antibody response in plasma samples collected before the onset of RA.

Methods: A case-control study was preformed within the Medical Biobank of Northern Sweden. The study included 251 individuals who donated in total 422 plasma samples predating the onset of clinical symptoms of RA, and 198 population-based controls from the same cohort. The median (IQR) predating time until onset of RA was 5.2 (6.2) years. For 192 individuals diagnosed with RA, plasma was available from the time point of RA diagnosis, and 152 of these patients had also donated plasma before the onset of symptoms. All samples were analysed by in-house ELISAs for the presence of antibodies to virulence factor arginine gingipainB (RgpB) purified from P. gingivalis, and a citrullinated peptide (denoted CPP3) derived from the P. gingivalis PAD enzyme. Based on ROC curve analysis on RA patients and controls, a cut-off for anti-CPP3 IgG positivity was set at the 96th percentile. The anti-P. gingivalis antibody data was evaluated in relation to the development of the classical ACPA response.

Results: The concentration of anti-RgpB IgG levels was significantly increased in RA patients (mean±SEM; 114.4±16.9 AU/ml), and importantly also in the pre-symptomatic individuals (152.7±14.8 AU/ml), when compared to controls (82.2±12.1 AU/ml, p < 0.001 for both). Antibodies against CPP3 were detected in 8% of the RA population, and in 5% of pre-symptomatic individuals, with elevated levels in both RA patients (9.29±1.81 AU/ml) and in pre-symptomatic individuals (4.33±0.59 AU/ml), compared to controls (2.36±0.58 AU/ml, p < 0.001 for both). The anti-CPP3 antibody response followed the classical ACPA response, with increasing antibody levels over time, whilst the anti-RgpB IgG response was stable in pre-symptomatic individuals during the pre-dating time and (if anything) showed a trend towards lower levels after RA diagnosis, potentially as a result of anti-inflammatory treatment.

Conclusion: Antibody levels against P. gingivalis were significantly increased in RA patients compared to controls, and more importantly, these antibodies were detected years before onset of symptoms of RA, supporting an aetiological role for P. gingivalis in the development of autoimmunity and autoimmune disease in a subset of RA patients.


Disclosure: L. Johansson, None; N. Sherina, None; N. Kharlamova, None; B. Larsson, None; L. Israelsson, None; S. Rantapaa-Dahlqvist, None; K. Lundberg, None.

To cite this abstract in AMA style:

Johansson L, Sherina N, Kharlamova N, Larsson B, Israelsson L, Rantapaa-Dahlqvist S, Lundberg K. Plasma Concentrations of Antibodies to Porphyromonas Gingivalis Are Increased before Onset of Symptom of Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/plasma-concentrations-of-antibodies-to-porphyromonas-gingivalis-are-increased-before-onset-of-symptom-of-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/plasma-concentrations-of-antibodies-to-porphyromonas-gingivalis-are-increased-before-onset-of-symptom-of-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology